908 Devices Inc. (NASDAQ:MASS) VP John Kenneweg sold 10,000 shares of the stock in a transaction on Friday, July 16th. The stock was sold at an average price of $32.27, for a total transaction of $322,700.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
John Kenneweg also recently made the following trade(s):
- On Wednesday, June 16th, John Kenneweg sold 10,000 shares of 908 Devices stock. The stock was sold at an average price of $39.27, for a total transaction of $392,700.00.
Shares of MASS stock opened at $31.90 on Wednesday. The company has a quick ratio of 16.89, a current ratio of 17.62 and a debt-to-equity ratio of 0.11. The company has a fifty day moving average price of $38.54. 908 Devices Inc. has a one year low of $30.71 and a one year high of $79.60.
MASS has been the subject of several recent research reports. Zacks Investment Research upgraded shares of 908 Devices from a “sell” rating to a “hold” rating in a report on Wednesday. SVB Leerink reduced their target price on shares of 908 Devices from $70.00 to $65.00 and set an “outperform” rating for the company in a report on Friday, May 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. 908 Devices presently has a consensus rating of “Buy” and an average target price of $68.00.
Several institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC raised its position in shares of 908 Devices by 145.4% in the first quarter. ARK Investment Management LLC now owns 1,072,866 shares of the company’s stock valued at $52,034,000 after purchasing an additional 635,618 shares during the period. BlackRock Inc. raised its position in shares of 908 Devices by 174.6% in the first quarter. BlackRock Inc. now owns 823,809 shares of the company’s stock valued at $39,955,000 after purchasing an additional 523,809 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of 908 Devices in the fourth quarter valued at about $32,632,000. Sands Capital Management LLC bought a new position in shares of 908 Devices in the fourth quarter valued at about $22,389,000. Finally, Primecap Management Co. CA raised its position in shares of 908 Devices by 1.1% in the first quarter. Primecap Management Co. CA now owns 328,600 shares of the company’s stock valued at $15,937,000 after purchasing an additional 3,600 shares during the period. 31.30% of the stock is currently owned by institutional investors.
908 Devices Company Profile
908 Devices Inc develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Featured Story: Cryptocurrencies
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.